St. Paul, MN — Kindeva Drug Delivery (Kindeva) and Breath of Life International (BOL Pharma or BOL) have agreed to the use of low GWP propellants in multiple inhaled cannabinoid products. Kindeva will develop novel formulations of BOL Pharma’s cannabinoid-based drug products delivered by Kindeva’s pressurized metered-dose inhaler (pMDI) technology using the next generation of low GWP propellants. Subject to all required regulatory approvals, the products under development are targeted to treat chronic neuropathic pain. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products using low GWP propellants, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis.

Read more here.